1. Home
  2. AIRI vs ALLR Comparison

AIRI vs ALLR Comparison

Compare AIRI & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Industries Group

AIRI

Air Industries Group

N/A

Current Price

$3.31

Market Cap

16.9M

Sector

Industrials

ML Signal

N/A

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

N/A

Current Price

$1.22

Market Cap

19.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIRI
ALLR
Founded
1979
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.9M
19.3M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
AIRI
ALLR
Price
$3.31
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.50
AVG Volume (30 Days)
154.2K
156.2K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
36.92
N/A
EPS
N/A
N/A
Revenue
$55,108,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.53
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.97
N/A
52 Week Low
$2.55
$0.61
52 Week High
$4.17
$2.35

Technical Indicators

Market Signals
Indicator
AIRI
ALLR
Relative Strength Index (RSI) 51.06 67.32
Support Level $3.18 $0.99
Resistance Level $3.34 $1.31
Average True Range (ATR) 0.17 0.12
MACD 0.01 0.04
Stochastic Oscillator 60.92 68.24

Price Performance

Historical Comparison
AIRI
ALLR

About AIRI Air Industries Group

Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.

Share on Social Networks: